araag2/HINT huggingface dataset:
Clinical trial NCT02465437 (phase 2, status: active, not recruiting)
Conditions: diffuse cutaneous systemic sclerosis
ICD codes: A06.7, A22.0, A26.0, A32.0, A36.3, A43.1, B38.3
Drugs: jbt-101, placebo, part b open-label extension
SMILES: [H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Part A

          -  Diffuse cutaneous systemic sclerosis

          -  Have skin thickening from SSc in a body area suitable for repeat biopsy

          -  Disease duration ≤ 3 years from the first non-Raynaud's phenomenon or >3 years and ≤ 6
             years from the first non-Raynaud's phenomenon and high sensitivity C-reactive protein
             > 3 mg/L, high sensitivity interleukin-6 > 5 pg/mL, or increase in mRSS ≥ 5 points
             over the last 6 months with total RSS ≥ 12.

          -  Stable treatment for SSc for at least 28 days before Visit 1

        Part B

        •Completion of dosing in Part A without permanent discontinuation of study product because
        of safety or tolerability reasons.

        Exclusion Criteria (Part A and B):

          -  Severe or unstable systemic sclerosis

          -  Significant diseases or conditions other than systemic sclerosis that may influence
             response to the study product or safety;

          -  Any one of the following values for laboratory tests at Screening:

               1. A positive pregnancy test (or at Visit 1);

               2. Hemoglobin < 10 g/dL

               3. Neutrophils < 1.0 x 10^9/L

               4. Platelets < 75 x 10^9/L

               5. Creatinine clearance < 50 ml/min according to modified Cockcroft-Gault equation

               6. Serum transaminases > 2.0 x upper normal limit

               7. Total bilirubin ≥ 1.5 x upper limit of normal

          -  Any other condition that, in the opinion of the Principal Investigator, is clinically
             significant and may put the subject at greater safety risk, influence response to
             study product, or interfere with study assessments.
Clinical trial NCT02465450 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: jbt-101 (lenabasum)
SMILES: [H][C@@]12CC(=CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documentation of a CF diagnosis as evidenced by 1 or more clinical features consistent
             with the CF phenotype and 1 or more of the following criteria:

               1. Sweat chloride equal to or greater than 60 mEq/L by quantitative pilocarpine
                  iontophoresis test;

               2. Two well-characterized mutations in the CFTR gene

          -  FEV1 ≥ 40% predicted corrected

          -  Stable treatment of CF for 14 days before Visit 1

        Exclusion Criteria:

          -  Severe or unstable CF, such as:

               1. Intravenous antibiotic treatment within 14 days before Visit 1

               2. Treatment with any corticosteroids > 10 mg per day or > 20 mg every other day
                  oral prednisone or equivalent within 14 days before Visit 1

          -  Any one of the following values for laboratory tests at Screening:

               1. A positive pregnancy test (or at Visit 1);

               2. Hemoglobin < 10 g/dL

               3. Neutrophils < 1.0 x 10~9/L

               4. Platelets < 75 x 10~9/L

               5. Creatinine clearance < 50 ml/min according to modified Cockcroft-Gault equation

               6. Serum transaminases > 2.5 x upper normal limit

               7. Total bilirubin ≥ 1.5 x upper limit of normal

          -  Any other condition that, in the opinion of the Principal Investigator, is clinically
             significant and may put the subject at greater safety risk, influence response to
             study product, or interfere with study assessments.
Clinical trial NCT02465580 (phase 2, status: unknown status)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: hril-2 active, hril-2 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet the American College of Rheumatology criteria for the diagnosis of SLE，1997.

          -  Under standard treatment (≥ 2 months) at the time of inclusion

          -  Background treatment failed to control flares or to permit prednisone tapering

          -  With at least one of the following manifestations: thrombocytopenia,
             disease-associated rash, mouth ulcer, non-infectious type of fever, active vasculitis,
             renal disorder(proteinuria>0.5g/day), neuropsychiatric SLE.

          -  Positive for at least one of the following laboratory tests: ANA>1:160, anti-dsDNA,
             immunoglobulin>20g/L, decreased C3 or C4, leukopenia<3×10^9/L,
             thrombocytopenia<100×10^9/L;

          -  SLE disease activity index(SLEDAI) ≥ 8.

          -  Negative HIV test.

          -  Negative for hepatitis B and C virus.

          -  Negative urine pregnancy test.

          -  Written informed consent form.

        Exclusion Criteria:

          -  Sever chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III
             NYHA), hepatic insufficiency (transaminases> 3N) )

          -  Serious infection such as bacteremia, sepsis;

          -  Cancer or history of cancer cured for less than five years (except in situ carcinoma
             of the cervix or Basocellular carcinoma);

          -  High-dose steroid pulse therapy (>1.5mg/kg) or IV bolus of corticosteroids in the last
             2 months.

          -  History of administration of rituximab or other biologics;

          -  Purified protein derivative (tuberculin) >10mm

          -  Mental disorder or any other chronic illness or drug-abuse that could interfere with
             the ability to comply with the protocol or to give information;

          -  Inability to comply with IL-2 treatment regimen.
Clinical trial NCT02468700 (phase 2, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Had a known history of dry eye disease

          -  Had a minimal Corneal Fluorescein Staining Score and OSDI score in each eye

        Exclusion Criteria:

          -  History of intraocular inflammation in either eye

          -  Use of the anti-inflammatory or immunomodulating agents ocular or systemic for the
             duration of the study

          -  Uncontrolled glaucoma or is on medications to treat glaucoma

          -  History of IOP spikes in either eye

          -  Active epiphora
Clinical trial NCT02470039 (phase 2, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin 338 (gipet i), insulin glargine, placebo
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age of 18-70 years (both inclusive) at the time of signing informed consent

          -  Body mass index of 25.0-40.0 kg/m^2 (both inclusive)

          -  Subject diagnosed (clinically) with type 2 diabetes mellitus for at least 180 days
             prior to the day of screening

          -  Insulin naïve subject; however, short term insulin treatment for a maximum of 14 days
             prior to the day of screening is allowed, as is prior insulin treatment for
             gestational diabetes

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to the trial products or related products

          -  Any disorder which in the investigator's opinion might jeopardise subject's safety or
             compliance with the protocol

          -  Presence of clinically significant gastrointestinal disorders potentially affecting
             absorption of drugs and/or nutrients, as judged by the investigator
Clinical trial NCT02472080 (phase 2, status: terminated)
Conditions: thyroid cancer
ICD codes: C73, D34, D44.0, Z85.850
Drugs: gemcitabine -oxaliplatine combination
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    inefficiency
  
Eligibility criteria:

        "Main Inclusion criteria

          1. Histologically confirmed differentiated or poorly differentiated thyroid cancer that
             is metastatic or unresectable

          2. Patients refractory to radio iodine

          3. Radiologic evidence of clinically relevant disease progression (as per RECIST 1.1)

          4. Measurable disease (by RECIST Version 1.1 criteria)

          5. ECOG performance status of ≤ 1

          6. Adequate hematologic, renal and liver function

          7. Negative serum pregnancy test in premenopausal women.

          8. Signed informed consent

        Main Non-Inclusion criteria

          1. Other histological subtypes of thyroid tumors: anaplastic, medullary, lymphoma or
             sarcoma

          2. Active CNS metastases

          3. Prior chemotherapy. Patients treated previously with molecular targeted therapies
             could be included.

          4. Severe, acute or chronic medical or psychiatric condition or laboratory abnormality
             which in the judgment of the investigator would make the patient inappropriate for
             entry into this study"
Clinical trial NCT02472353 (phase 2, status: terminated)
Conditions: breast cancer, breast tumors
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: metformin, doxorubicin
SMILES: CSCC[C@H](N)C(O)=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    did not meet target accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Breast cancer requiring neoadjuvant or adjuvant therapy with doxorubicin

          -  Complete metabolic panel demonstrating adequate organ functions as defined by the
             following: Aspartate transaminase (AST) less than 2.5 times Upper Limit of Normal
             (ULN); Alanine transaminase (ALT) less than 2.5 times ULN; alkaline phosphatase less
             than 2.5 times ULN; serum creatinine less than 1.5 mg/dL; serum bilirubin less than
             ULN

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Age greater than or equal to 21 years

        Exclusion Criteria:

          -  Known diabetes

          -  History of cardiac arrhythmias or symptomatic cardiac disease

          -  Currently taking antiarrhythmic medications, beta-blockers, or other rate controlling
             cardiac medications

          -  Currently taking metformin and/or sulfonylureas

          -  Known hypersensitivity or intolerance to metformin

          -  Baseline ejection fraction of less than 50% measured by echocardiogram

          -  Known hypersensitivity to contrast used during echocardiogram

          -  Risk factors associated with increased risk of metformin-associated lactic acidosis
             (e.g. congestive heard failure, history of acidosis, habitual intake of 3 or more
             alcoholic beverages per day)

          -  Pregnant or breast feeding
Clinical trial NCT02472535 (phase 2, status: completed)
Conditions: homozygous familial hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: mbx-8025 50 mg (dose escalation period 1), mbx-8025 50 mg or 100 mg (dose escalation period 2), mbx-8025 50 mg, 100 mg or 200 mg (dose escalation period 3)
SMILES: CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC1=CC=C(OCC(O)=O)C(C)=C1, CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC1=CC=C(OCC(O)=O)C(C)=C1, CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC1=CC=C(OCC(O)=O)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Must have given written informed consent (signed and dated) and any authorizations
             required by local law and be able to comply with all study requirements.

          2. Male or female with HoFH confirmed by genotype (two mutant alleles at the LDL-Receptor
             (LDL-R) gene locus or double heterozygotes LDL-R/Apo-B).

          3. 18 years of age or older.

          4. Existing lipid lowering therapies (statins, cholesterol absorption inhibitors, bile
             acid sequestrants, nicotinic acid and their combinations, low-density lipoprotein
             (LDL) LDL-C apheresis) on a stable regimen for at least four weeks before screening
             visit.

          5. Stable lipid lowering diet compatible with a Step I diet of the American Heart
             Association (AHA).

          6. Fasting LDL-C ≥ 4.8 mmol/L (≥ 185.6 mg/dL) during screening.

          7. For females or males of reproductive potential, use of at least one barrier
             contraceptive and a second effective birth control method during the study and for at
             least two weeks after the last dose.

        Exclusion Criteria:

          1. Treatment with lomitapide or mipomersen within two months of screening.

          2. Heart Failure (HF) with New York Heart Association (NYHA) class III and class IV or a
             Left ventricular ejection fraction (LVEF) of less than 30%.

          3. Uncontrolled cardiac arrhythmia during the past three months of screening.

          4. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary
             artery bypass graft or stroke during the past three months of screening.

          5. Planned cardiac surgery, or planned revascularization, in the next four months.

          6. Uncontrolled hypertension.

          7. Aspartate transaminase (AST) or Alanine transaminase (ALT) ≥ 3 times the Upper Limit
             of Normal (ULN).

          8. Unexplained creatine kinase (CK) ≥ 5 times the upper limit of normal (ULN).

          9. For females, pregnancy or breast-feeding.

         10. Any other condition(s) that would compromise the safety of the patient or compromise
             the quality of the clinical study as judged by the Investigator and/or Medical
             Monitor.
Clinical trial NCT02473094 (phase 2, status: terminated)
Conditions: rectal neoplasms, adenocarcinoma, carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: capecitabine, metformin, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older;

          -  biopsy proven poorly differentiated carcinoma or adenocarcinoma of the rectum;

          -  lesions located within 12 cm of the anal verge (from colonoscopy assessment);

          -  ability to tolerate oral treatment;

          -  locally advanced tumor, classified by the presence of positive regional lymph nodes or
             primary tumor invasion beyond the serosa (T3 or T4), assessed by MRI;

          -  eligibility for curative surgery (no distant metastasis or invasion of bony structures
             of the pelvis);

          -  Performance Status (PS) Eastern Cooperative Oncology Group (ECOG) 0-2;

          -  adequate hematologic functions (hemoglobin ≥ 10 g / dL [5.6 mmol / L]; neutrophil
             count ≥ 1,500 / mm3 and platelet count ≥ 100,000 / mm3), adequate renal function
             (serum creatinine less than 1.5 times the UNL) and adequate hepatic function
             (bilirubin less than 1.5 times the UNL; aspartate aminotransferase and alanine
             aminotransferase less than 2.5 times the UNL);

        Exclusion Criteria:

          -  known hypersensitivity to metformin or its excipients;

          -  squamous carcinomas of the rectum or anal canal;

          -  chronic treatment with corticosteroids or other immunosuppressive agents;

          -  treatment with oral antidiabetic products;

          -  distant metastasis at diagnosis or tumor invasion of pelvic bone structures that may
             proscribe curative intent surgery;

          -  chronic or acute infections;

          -  use of drugs under study up to four weeks prior to randomization;

          -  pregnant or nursing patients;

          -  prior radiotherapy to the pelvic region;

          -  myocardial infarction up to six months prior to randomization, or uncontrolled
             ischemic heart disease;

          -  congestive heart insufficiency New York Heart Association (NYHA) III-IV.
Clinical trial NCT02474290 (phase 2/phase 3, status: completed)
Conditions: acute myeloid leukemia, hematopoietic stem cell transplantation
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  FLT3-ITD Positive AML

          -  Allo-HSCT Recipients

        Exclusion Criteria:

          -  cardiac dysfunction (particularly congestive heart failure)

          -  hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase> 2 times the upper limit
             of normal)

          -  renal dysfunction (creatinine clearance rate < 30 mL/min)

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
Clinical trial NCT02482428 (phase 2, status: completed)
Conditions: external genital warts
ICD codes: B88.3, S30.845S, S30.846S, S30.845A, S30.845D, S30.846A, S30.846D
Drugs: investigational treatment, aldara
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Circumcised male 18-60 years

          -  Clinical diagnosis of external genital warts

          -  Agree to remain abstinent or to use condoms during intercourse for the duration of the
             study

          -  Agree to digital photographs of treated area

        Exclusion Criteria:

          -  Any treatment of genital warts within one month of treatment start

          -  HPV vaccination

          -  presence of warts larger than 200 mm2

          -  Genital herpes within one month of treatment start

          -  History of Bowenoid papulosis

          -  significant illness within 2 weeks of treatment start

          -  use of other investigational drugs

          -  known hypersensitivity to study drugs or constituents

          -  history of ECG abnormalities

          -  History of significant heart conditions

          -  Impaired renal function

          -  Abnormal liver function

          -  History of immunodeficiency disease

          -  Drug or alcohol abuse

          -  Immunosuppressive therapies

          -  Malignancies in the past 5 years

          -  hypertrophic scarring
Clinical trial NCT02484378 (phase 2, status: completed)
Conditions: acute coronary syndromes
ICD codes: I24.0
Drugs: cer-001, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female greater than 18 years of age

          -  Acute coronary syndrome (myocardial infarction or unstable agina)

          -  Angiographic evidence of coronary artery disease with suitable "target" coronary
             artery for IVUS evaluation

        Exclusion Criteria:

          -  Females of child-bearing potential

          -  Angiographic evidence of >50% stenosis of the left main artery

          -  Uncontrolled diabetes (HbA1C>10%)

          -  Hypertriglyceridemia (>500 mg/dL)

          -  Congestive heart failure (NYHA class III or IV)

          -  Ejection fraction <35%

          -  Uncontrolled hypertension (SBP >180 mm Hg)

          -  Known major hematologic, renal, hepatic, metabolic, gastrointestinal or endocrine
             dysfunction
Clinical trial NCT02484690 (phase 2, status: completed)
Conditions: choroidal neovascularization
ICD codes: H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211
Drugs: faricimab, ranibizumab, sham procedure
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment-naive with CNV secondary to AMD, with subfoveal CNV or juxtafoveal CNV with
             a subfoveal component related to the CNV activity by FFA or SD-OCT

          -  Active CNV

        Exclusion Criteria:

          -  CNV due to causes other than AMD

          -  Subretinal hemorrhage, fibrosis, or atrophy involving either the fovea or more than
             50% of the total lesion area

          -  Cataract surgery within 3 months of baseline, or any other previous intraocular
             surgery

          -  Major illness or surgery within 1 month prior to Screening

          -  Glycosylated hemoglobin (HbA1c) above 7.5%

          -  Uncontrolled blood pressure
Clinical trial NCT02489461 (phase 2/phase 3, status: completed)
Conditions: hiv-1-infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: vm-1500, efavirenz, antiretroviral therapy (art)
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. Signed Patient Information and Informed Consent Form.

          2. Males and females, age ≥ 18 years.

          3. HIV-1 infection, confirmed serologically in IFA or immunoblot analysis (or documented
             HIV-1 infection).

          4. Clinically stable HIV infection (clinical stages 1 or 2 according to the WHO
             classification).

          5. Indications (in the Investigator's opinion) for ART, according to the WHO Summary
             Guideline for use of antiretroviral drugs in HIV prevention and treatment (2013).

          6. HIV-1 RNA plasma level ≥ 5 000 copies/ml at screening.

          7. СD4+ Т-cells number > 200 cells/mm3 at screening.

          8. Laboratory parameters as follows:

        White blood cells ≥ 2900/mm3 (2,9 x 109 cells/l) Absolute neutrophils ≥ 1500/mm3 (1,5 x 109
        cells/l) Platelets ≥ 100000/mm3 (100 x 109 cells/l) Hemoglobin ≥ 9.0 g/dl Total bilirubin ≤
        1.5 x ULN AST and ALT≤ 2.5 x ULN Renal function GFR > 60 ml/min

        Exclusion Criteria:

          1. Primary HIV-1 resistance to ART. Viral resistance mutations are defined as any basic
             mutations of resistance to NNRTIs, according to the updated list of VIH-1 resistance
             mutations (International AIDS society, 2013), associated with drug resistance in any
             genotype.

          2. History of antiretroviral therapy (ART), including for the prevention of vertical
             transmission of HIV.

          3. Acute hepatitis or hepatic cirrhosis of any etiology; anti-HCV antibodies or HBsAg at
             screening.

          4. Signs of acute infection or positive test result for syphilis, hepatitis A, Toxoplasma
             gondii, cytomegalovirus, gonorrhea, Chlamydia trachomatis during 30 days before
             screening.

          5. Opportunistic infections of the Category C (Centers of Disease Control (CDC), 2008),
             excluding Kaposi's sarcoma not requiring systemic therapy.

          6. History of tuberculosis of any localization, or tuberculosis at screening, according
             to x-ray examination.

          7. History of malignant tumors (except basal cell carcinoma, squamous cell carcinoma, or
             cervical carcinoma in situ, eliminated and cured ≥ 5 years ago).